BG
Bellevue Group Portfolio holdings
AUM
$4.54B
1-Year Return
22.5%
This Quarter Return
+16.96%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$1.82B
AUM Growth
+$366M
(+25%)
Cap. Flow
+$143M
Cap. Flow
% of AUM
7.84%
Top 10 Holdings %
Top 10 Hldgs %
36.79%
Holding
154
New
14
Increased
81
Reduced
30
Closed
17
Top Buys
| 1 |
Humana
HUM
|
$19.6M |
| 2 |
Evolent Health
EVH
|
$17.1M |
| 3 |
Teladoc Health
TDOC
|
$16.7M |
| 4 |
Bristol-Myers Squibb
BMY
|
$9.97M |
| 5 |
AVDR
Avedro, Inc Common Stock
AVDR
|
$9.2M |
Top Sells
| 1 |
CELG
Celgene Corp
CELG
|
$60.4M |
| 2 |
Ionis Pharmaceuticals
IONS
|
$6.49M |
| 3 |
Amgen
AMGN
|
$5.79M |
| 4 |
MacroGenics
MGNX
|
$4.97M |
| 5 |
Insmed
INSM
|
$4.35M |
Sector Composition
| 1 | Healthcare | 91.36% |
| 2 | Industrials | 1.12% |
| 3 | Technology | 0.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDSO
76
DELISTED
Medidata Solutions, Inc.
MDSO
| $5.16M | 0.28% |
70,474
+21,263
| +43% | +$1.56M |
|
77
Gilead Sciences
GILD
$140B
| $5.06M | 0.28% |
77,800
-45,200
| -37% | -$2.94M |
|
|
VCRA
78
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $5M | 0.28% |
158,214
+125,264
| +380% | +$3.96M |
|
79
Neuronetics
STIM
$219M
| $4.5M | 0.25% |
295,337
+129,937
| +79% | +$1.98M |
|
80
Hologic
HOLX
$14.8B
| $4.36M | 0.24% |
90,000
| – | – |
|
81
Coherus Oncology, Inc. Common Stock
CHRS
$152M
| $4.33M | 0.24% |
317,135
-41,800
| -12% | -$570K |
|
|
MTLS
82
Materialise
MTLS
$294M
| $4.23M | 0.23% |
268,409
+53,217
| +25% | +$838K |
|
|
HZNP
83
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $4.2M | 0.23% |
158,800
-9,700
| -6% | -$256K |
|
84
Incyte
INCY
$16.7B
| $4.17M | 0.23% |
48,500
-10,150
| -17% | -$873K |
|
|
AMED
85
DELISTED
Amedisys
AMED
| $4.15M | 0.23% |
33,656
+8,452
| +34% | +$1.04M |
|
|
BLUE
86
DELISTED
bluebird bio
BLUE
| $3.63M | 0.2% |
1,783
+787
| +79% | +$1.6M |
|
87
Penumbra
PEN
$10.9B
| $3.48M | 0.19% |
23,637
-413
| -2% | -$60.7K |
|
88
Viatris
VTRS
$12B
| $3.46M | 0.19% |
122,000
-74,950
| -38% | -$2.12M |
|
|
SGEN
89
DELISTED
Seagen Inc. Common Stock
SGEN
| $3.35M | 0.18% |
45,800
+10,800
| +31% | +$791K |
|
|
SWAV
90
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $3.35M | 0.18% |
+100,000
| New | +$3.35M |
|
91
Exelixis
EXEL
$10.1B
| $3.34M | 0.18% |
140,500
+46,500
| +49% | +$1.11M |
|
92
Masimo
MASI
$7.77B
| $3.15M | 0.17% |
22,780
| – | – |
|
93
CVS Health
CVS
$93.5B
| $3.11M | 0.17% |
57,627
+31,802
| +123% | +$1.72M |
|
94
Henry Schein
HSIC
$8.22B
| $3.05M | 0.17% |
50,662
-14,832
| -23% | -$891K |
|
95
Johnson & Johnson
JNJ
$431B
| $2.8M | 0.15% |
20,000
| – | – |
|
96
Acadia Pharmaceuticals
ACAD
$4.3B
| $2.79M | 0.15% |
103,800
+8,000
| +8% | +$215K |
|
|
97
Amgen
AMGN
$151B
| $2.76M | 0.15% |
14,500
-30,450
| -68% | -$5.79M |
|
98
FibroGen
FGEN
$45.7M
| $2.65M | 0.15% |
1,952
+672
| +53% | +$913K |
|
|
SAGE
99
DELISTED
Sage Therapeutics
SAGE
| $2.59M | 0.14% |
16,300
+5,700
| +54% | +$907K |
|
100
argenx
ARGX
$44.9B
| $2.48M | 0.14% |
19,900
+7,300
| +58% | +$911K |
|